In an in vitro experiment the “Lipid modifying agent” clofibrate, but not bezafibrate reversed UVB-light-mediated expression of psoriasis – related inflammatory cytokines (interleukin-6, interleukin-8).[61] Fluvastatin and pravastatin have the potential to inhibit Th17 cell chemotaxis thus lowering immune cell infiltration of psoriatic skin.[62] Anti-proliferative effect of novel COX2 inhibitors on HaCaT keratinocytes was proven in an in vitro experiment and possible therapeutic use in psoriasis was supposed. This evidence concerns the gene CXCL8 and psoriasis.